SAN JOSE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today the launch of the BD FACSAria™ III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.
"As the pioneer in flow cytometry, BD Biosciences' goal is to expand the range of applications that can benefit from this technology by building innovative, powerful tools that are easier to use and more accessible to a larger number of life science researchers," said James Glasscock, President, BD Biosciences – Cell Analysis. "The new BD FACSAria III system reflects this effort by providing researchers the flexibility to configure a system that meets their application requirements and budgets today, with the ability to expand its capabilities later to meet future needs."
Innovations in the new BD FACSAria III Cell Sorting System include:
- A next-generation gel coupled cuvette in the flow cell ensures that the system's lasers are focused precisely on the sample stream and that they generate the greatest signal to maximize the amount of emitted light. Most importantly, it improves collection efficiency and optimizes the resolution needed for multicolor applications, even at high-speed sorting settings.
- The instrument's advanced optical system works efficiently to maximize signal detection as well as greatly increase the sensitivity and resolution for each color in a multicolor assay. Enhanced sensitivity and resolution helps readily identify and sort dim cell populations. In addition, the system's next-generation flow cell is designed to improve resolution for side population applications and DNA cell cycle analyses.
- A new expandable architecture uses an X-mount optical plate that allows the system to be expanded to support up to six laser wavelengths — 633 nm, 561 nm, 488 nm, 445 nm, 405 nm and 375 nm — as well as up to 20 detector positions that can be used simultaneously.
- A backwards-compatible architecture allows customers to upgrade existing instruments to the new BD FACSAria III platform. With a field upgrade, laboratories with a BD FACSAria or BD FACSAria II system can upgrade to the new capabilities of the BD FACSAria III system.
For more information on the BD FACSAria III Cell Sorting System, please visit: www.bdbiosciences.com/aria
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD-Becton Dickinson
Back to top
RELATED LINKSRelated medicine technology :1
. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR2
. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast3
. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications4
. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium5
. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference6
. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices7
. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 20098
. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting9
. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference10
. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 200911
. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results